Pregnancy and commonly used drugs in hematology practice.

@article{Koren2010PregnancyAC,
  title={Pregnancy and commonly used drugs in hematology practice.},
  author={Gideon Koren and Michael Lishner},
  journal={Hematology. American Society of Hematology. Education Program},
  year={2010},
  volume={2010},
  pages={
          160-5
        }
}
  • G. Koren, M. Lishner
  • Published 4 December 2010
  • Medicine
  • Hematology. American Society of Hematology. Education Program
When a woman suffering from a hematological condition is contemplating pregnancy, she may need to continue the use of medications that do not have sufficient evidence of fetal safety. We discuss the evidence existing for some therapies of major hematological conditions in the context of major principles in clinical teratology. It is critical to always balance the potential fetal risks of the drug in question against the maternal and fetal risks of the untreated hematological condition. 
Management of hemopoietic neoplasias during pregnancy.
  • S. Paydaş
  • Medicine
    Critical reviews in oncology/hematology
  • 2016
Chemotherapy in pregnancy.
TLDR
The care of a pregnant woman with cancer involves evaluation of competing maternal and fetal risks and benefits and the risks depend on the drugs used and the gestational age of the fetus.
Management and controversies of classical Hodgkin lymphoma in pregnancy
TLDR
Options for management of classical Hodgkin lymphoma within pregnancy are discussed, including the evidence for using ABVD and single agent vinblastine in the first trimester and the aim during pregnancy should be to minimize fetal toxicity and optimize perinatal outcomes.
Acute myeloid leukemia in the pregnant patient
  • X. Thomas
  • Medicine
    European journal of haematology
  • 2015
TLDR
Although acute myeloid leukemia (AML) mostly occurs in older patients, it could be seen in women of childbearing age, and it is admitted that it can be administered safely during the second and the third trimesters.
Acute myeloid leukemia in the pregnant patient.
  • X. Thomas
  • Medicine
    European journal of haematology
  • 2015
TLDR
Although acute myeloid leukemia (AML) mostly occurs in older patients, it could be seen in women of childbearing age, and it is admitted that it can be administered safely during the second and the third trimesters.
Management of Concurrent Pregnancy and Acute Lymphoblastic Malignancy in Teenaged Patients: Two Illustrative Cases and Review of the Literature.
TLDR
Two illustrative cases of teenage pregnancy complicated by acute lymphoblastic malignancy are presented, the available literature is reviewed, and suggestions for the therapeutic management of such cases in adolescent and young adult patients are offered.
Cytomorphological Analyses of Abnormal Blood Cells of Acute Leukemic Patients
TLDR
Three types of atypical cells such as tadpole shaped cell, tear drop shaped cell and rod shaped cell were observed in this study and highly significant difference was found among the age groups of male acute leukemic patients with respect to cell length and breadth of rodshaped cell.
...
...

References

SHOWING 1-10 OF 48 REFERENCES
Hydroxyurea use during pregnancy: A case report in sickle cell disease and review of the literature
A patient being treated for sickle cell disease with hydroxyurea (1 g/d) conceived, and drug treatment was discontinued at nine weeks gestational age. The pregnancy and delivery were complicated by
Hodgkin’s Disease during Pregnancy: Diagnostic and Therapeutic Management
TLDR
It is found that women affected by Hodgkin’s disease during their second or third trimester of pregnancy can safely carry their pregnancy to term and the pregnancy does not worsen the course of the illness and does not compromise long-term clinical remission and recovery.
HODGKIN'S DISEASE IN PREGNANCY.
Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia.
Use of proton pump inhibitors during pregnancy and breastfeeding.
TLDR
Data currently available suggest that omeprazole is not teratogenic in humans, and while information on other PPIs is limited, a systematic review of the evidence suggests that they are also notTeratogenic.
Risk of drug-induced congenital defects.
Hodgkin's disease in pregnancy: a report of three cases.
Three cases of Hodgkin's Disease in pregnancy, presenting at 26, 37 and 16 weeks respectively have been treated at this institution during the past five years. A successful outcome was achieved
Major malformations with valproic acid.
TLDR
There is compelling evidence that the risk of teratogenic risks is dose dependent and the risks appear to begin increasing at doses of 600 mg/d and to become more prominent at doses above 1000mg/d.
Maternal and foetal outcome following Hodgkin's disease in pregnancy.
TLDR
Pregnant women with Hodgkin's Disease had similar distribution of stages to the controls and their outcome with non-pregnant matched women who were of similar stage of disease, age at diagnosis, and calenderic year of treatment was not different.
Pregnancy-Induced Changes in Pharmacokinetics
  • G. Anderson
  • Medicine, Biology
    Clinical pharmacokinetics
  • 2005
TLDR
Evaluating the pharmacokinetic data of a variety of drugs during pregnancy and using a mechanistic-based approach can start to predict the effect of pregnancy for a large number of clinically used drugs.
...
...